Effect of C-xyloside on morphogenesis of the dermal epidermal junction in aged female skin. An ultrastuctural pilot study

European Journal of Dermatology, 21(2):191-6


L’Oréal Recherche, 188, rue Paul Hochart, BP 553, 94152 Chevilly-Larue, France.
L’Oréal Recherche, Clichy, France.
L’Oréal Recherche, Aulnay-sous-Bois, France.
Bioalternatives, Gençay, France.


A placebo-controlled randomized pilot study was performed on five postmenopausal women aged from 60 to 75 years. The women applied 320 mg (2 mg/cm(2)) of either placebo or 10% C-β-D-xylopyranoside-2-hydroxy-propane (C-xyloside) cream to each outer forearm twice daily for 3 months. At the end of the treatment, skin biopsies were collected from application areas on both forearms. Transmission electron microscope examinations revealed skin ultrastructural changes at the dermal epidermal junction (DEJ) after 10% C-xyloside application for 3 months. The morphological appearance of the DEJ showed strong improvements, with more homogeneous and regular lamina densa in the C-xyloside-treated compared to the placebo treated skin areas. The number of zones showing basement membrane re-duplication was indeed strikingly reduced on C-xyloside-treated skin. These ultrastructural results were further confirmed by a statistically significant increase in the expression levels of α6-integrin the and laminin-332, as estimated by immunohistochemistry.
Altogether, these data suggest that topical C-xyloside application in vivo may be efficient in inducing a better dermal-epidermal cohesion when such a junction is deficient, as is the case in photo-aged or chronologically aged skin. Moreover, a statistically significant increase in CD44 expression was noted in the epidermis of C-xyloside-treated compared to the placebo treated skin areas.

KEYWORDS: Skin ageing; Dermal epidermal junction; C-xyloside; Laminin 332; α 6-integrin subunit

Related posts

Check out Bioalternatives’ updates and experience new testing ideas

  • Bioassays, models and services
  • Posts and publications
  • Events
  • The legal basis for the processing is consent. Your e-mail address will only be communicated to the following recipients: the departments concerned and authorised by QIMA LIFE SCIENCE. This data is kept for as long as you are registered to the newsletter.

    You can access your data, rectify it, request its deletion or exercise your right to limit the processing of your data, withdraw your consent to the processing of your data at any time, oppose the processing of your data and you have a right to the portability of your data.

    Visit cnil.fr for more information on your rights.
    You can exercise all your rights using the following linkGestion des droits or by writing to dpo-qima@agencergpd.eu. If you feel, after contacting us, that your "Informatique et Libertés" rights are not being respected, you can submit a complaint to the CNIL.

  • The information collected on this form is recorded in a file used by QIMA Life Sciences to send you its newsletter.